Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Delayed Olaparib Maintenance in Recurrent Ovarian Cancer
NCT04377087Phase 2Terminated
- Start
- Jun 2020
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olaparib in ovarian cancer. Primary endpoint: Time to Next Therapy up to 35 months. Started Jun 2020; status: terminated.
02
Drugs
olaparib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT04377087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04377087.